Veraxa Biotech and OmniAb Partner to Develop Bispecific Antibody Drug Conjugate Program

Veraxa Biotech and OmniAb, Inc. have initiated a joint discovery partnership aimed at creating a bispecific antibody drug conjugate program. The collaboration will focus on leveraging both companies’ expertise to develop a novel therapeutic approach. Under the agreement, Veraxa Biotech will contribute its capabilities in antibody drug conjugate (ADC) development, while OmniAb will provide access to its OmniAb discovery platform. This platform is designed to generate a diverse range of human therapeutic antibodies. The partnership aims to combine these strengths to advance the development of bispecific antibody drug conjugates.

Newsflash | Powered by GeneOnline AI
Date: May 6, 2025

Author

Mark Chiang